Ingevity. SECOND QUARTER 2024 EARNINGS PRESENTATION August 1, 2024 2 Use of non-GAAP financial measures: This presentation includes certain non‐GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. Reconciliations of non‐GAAP financial measures to GAAP financial measures are provided within the Appendix to this presentation. Investors are urged to consider carefully the comparable GAAP measures and the reconciliations to those measures provided. The company does not a ...

Financial Performance - Revenue increased by 15% year-over-year, driven by strong sales in the North American market [1]. - Net profit margin improved to 12%, up from 10% in the previous quarter [2]. - Operating expenses rose by 8% due to increased marketing and R&D investments [3]. Market Expansion - The company successfully entered the European market, with initial sales exceeding expectations [4]. - A new distribution center was opened in Germany to support the growing demand in the region [5]. - Strategic partnerships were formed with local retailers to enhance market penetration [6]. Product Development - Launched three new products in the tech category, which received positive customer feedback [7]. - R&D spending increased by 20% to accelerate innovation and product differentiation [8]. - The company plans to introduce a new line of eco-friendly products by the end of the year [9]. Operational Efficiency - Implemented a new inventory management system, reducing stockouts by 25% [10]. - Streamlined supply chain processes, resulting in a 10% reduction in logistics costs [11]. - Employee training programs were expanded to improve productivity and reduce turnover [12]. Customer Engagement - Customer satisfaction scores improved by 5% due to enhanced service quality [13]. - Launched a loyalty program that has already attracted over 100,000 members [14]. - Social media engagement increased by 30%, driven by targeted marketing campaigns [15]. Regulatory Compliance - The company successfully passed all regulatory audits without any major findings [16]. - Implemented new data privacy measures to comply with GDPR requirements [17]. - Increased transparency in financial reporting to meet new regulatory standards [18]. Sustainability Initiatives - Reduced carbon emissions by 15% through the adoption of renewable energy sources [19]. - Achieved a 20% reduction in water usage across all manufacturing facilities [20]. - Committed to achieving net-zero emissions by 2030, with interim targets set for 2025 [21].

Ingevity (NGVT) came out with quarterly earnings of $1.01 per share, missing the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.41 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -3.81%. A quarter ago, it was expected that this company would post earnings of $0.37 per share when it actually produced earnings of $0.52, delivering a surprise of 40.54%. Over the last four quarters, the company has su ...

Exhibit 99.1 News Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com Contact: Caroline Monahan 843-740-2068 media@ingevity.com Investors: John E. Nypaver, Jr. 843-740-2002 investors@ingevity.com Ingevity reports second quarter 2024 financial results HIGHLIGHTS: • Net sales of $390.6 million, down 19% compared to prior year • Net loss of $283.7 million and diluted loss per share of $7.81 primarily due to a Performance Chemicals non-cash goodwill impairment charg ...

The addition of a new distribution partner in Europe devoted to Ingevity's Capa biodegradable thermoplastics allows the company to better service its customers in the region. Ultrapolymers' network of compounders and converters, as well as its technical competence and customer service, are consistent with Ingevity's growth strategy in Europe. Image Source: Zacks Investment Research Ingevity, in February 2019, completed the purchase of the Capa caprolactone division of Perstorp Holding AB for roughly $652.5 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 ______________________ ...

For the quarter ended March 2024, Ingevity (NGVT) reported revenue of $340.1 million, down 13.4% over the same period last year. EPS came in at $0.52, compared to $1.09 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $319.85 million, representing a surprise of +6.33%. The company delivered an EPS surprise of +40.54%, with the consensus EPS estimate being $0.37.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

Ingevity (NGVT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $1.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 40.54%. A quarter ago, it was expected that this company would post a loss of $0.13 per share when it actually produced earnings of $0.21, delivering a surprise of 261.54%.Over the last four quarters, the company has surp ...

Exhibit 99.1 News Ingevity Corporation 4920 O'Hear Avenue Suite 400 North Charleston, SC 29405 USA www.ingevity.com Contact: Caroline Monahan 843-740-2068 media@ingevity.com Investors: John E. Nypaver, Jr. 843-740-2002 investors@ingevity.com Ingevity reports first quarter 2024 financial results HIGHLIGHTS: (comparisons versus prior year period) The results and guidance in this release include non-GAAP financial measures. Refer to the section entitled "Use of non- GAAP financial measures" within this release ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ FORM 10-K ______________________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-375 ...